These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 9014720)
1. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view. Bishop MC Br J Urol; 1996 Dec; 78(6):921-7; discussion 927-8. PubMed ID: 9014720 [TBL] [Abstract][Full Text] [Related]
2. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. Lin BJ; Chen KK; Chen MT; Chang LS Urology; 1994 Jun; 43(6):834-7. PubMed ID: 8197647 [TBL] [Abstract][Full Text] [Related]
3. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial. Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308 [TBL] [Abstract][Full Text] [Related]
5. Oestrogen dosage in prostatic cancer: the threshold effect? Bishop MC; Lemberger RJ; Selby C; Lawrence WT Br J Urol; 1989 Sep; 64(3):290-6. PubMed ID: 2679960 [TBL] [Abstract][Full Text] [Related]
6. Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma. Russo P; Liguori G; Heston WD; Huryk R; Yang CR; Fair WR; Whitmore WF; Herr HW Cancer Res; 1987 Nov; 47(22):5967-70. PubMed ID: 3664500 [TBL] [Abstract][Full Text] [Related]
7. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients. Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620 [TBL] [Abstract][Full Text] [Related]
8. The effects of diethylstilbestrol and medroxyprogesterone acetate on kinetics and production of testosterone and dihydrotestosterone in patients with prostatic carcinoma. Nolten WE; Sholiton LJ; Srivastava LS; Knowles HC; Werk EE J Clin Endocrinol Metab; 1976 Dec; 43(6):1226-33. PubMed ID: 1002814 [TBL] [Abstract][Full Text] [Related]
9. Endocrine effects of oestrogen treatment in patients with prostatic cancer. Schnorr D; Mebel M; Dörner G; Stahl F; Rohde W Eur Urol; 1976; 2(2):85-8. PubMed ID: 971678 [TBL] [Abstract][Full Text] [Related]
10. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. Chang A; Yeap B; Davis T; Blum R; Hahn R; Khanna O; Fisher H; Rosenthal J; Witte R; Schinella R; Trump D J Clin Oncol; 1996 Aug; 14(8):2250-7. PubMed ID: 8708714 [TBL] [Abstract][Full Text] [Related]
11. The role of diethylstilbestrol in the treatment of prostate cancer. Malkowicz SB Urology; 2001 Aug; 58(2 Suppl 1):108-13. PubMed ID: 11502463 [TBL] [Abstract][Full Text] [Related]
13. Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research Group. Emtage LA; Trethowan C; Hilton C; Kelly K; Blackledge GR Am J Clin Oncol; 1988; 11 Suppl 2():S173-5. PubMed ID: 2977273 [TBL] [Abstract][Full Text] [Related]
14. A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients. Klioze SS; Miller MF; Spiro TP Am J Clin Oncol; 1988; 11 Suppl 2():S176-82. PubMed ID: 3149455 [TBL] [Abstract][Full Text] [Related]
15. Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilboestrol and estramustine. Bishop MC; Selby C; Taylor M Br J Urol; 1985 Oct; 57(5):542-7. PubMed ID: 3904908 [TBL] [Abstract][Full Text] [Related]
16. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation. Kreis W; Ahmann FR; Jordan VC; de Haan H; Scott M Br J Urol; 1988 Oct; 62(4):352-4. PubMed ID: 2973364 [TBL] [Abstract][Full Text] [Related]
17. Medical castration of males with megestrol acetate and small doses of diethylstilbestrol. Geller J; Albert J; Yen SS; Geller S; Loza D J Clin Endocrinol Metab; 1981 Mar; 52(3):576-80. PubMed ID: 6161942 [TBL] [Abstract][Full Text] [Related]
18. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer. Debruyne FM Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760 [TBL] [Abstract][Full Text] [Related]
19. Bilateral orchiectomy for carcinoma of prostate. Response of serum testosterone and clinical response to subsequent estrogen therapy. Klugo RC; Farah RN; Cerny JC Urology; 1981 Jan; 17(1):49-50. PubMed ID: 7456197 [TBL] [Abstract][Full Text] [Related]
20. Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07. Pilepich MV; Buzydlowski JW; John MJ; Rubin P; McGowan DG; Marcial VA Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):175-80. PubMed ID: 7721614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]